Dec 31, 2025 • AD HOC NEWS
NEUTRAL
The Truth About GSK plc (ADR): Is Wall Street Sleeping On This Pharma Beast?
GSK plc (ADR) is presented as a stable pharmaceutical giant focusing on vaccines, respiratory treatments, and oncology, offering steady growth and dividends rather than speculative highs. The article suggests that while it lacks the viral hype of meme stocks or AI, its fundamental business strength and global footprint make it a strong candidate for long-term, fundamentals-first investors looking to diversify their portfolios. Investors should consider its defensive nature, income potential, and the inherent risks of the pharma industry such as lawsuits and patent expirations.
Dec 29, 2025 • MyChesCo
BULLISH
FDA Clears GSK’s Twice-Yearly Asthma Drug, Signaling Shift in Biologic Care
The FDA has approved GSK's Exdensur, a twice-yearly biologic treatment for severe asthma with an eosinophilic phenotype, marking the first ultra-long-acting option in the US. This approval, based on Phase III trials showing significant reductions in asthma exacerbations, aims to reduce the treatment burden and improve consistency of care for the estimated 2 million Americans with severe asthma. GSK hopes this extended-interval treatment will increase the adoption of biologics among eligible patients.
Dec 28, 2025 • MarketBeat
BULLISH
Bard Financial Services Inc. Purchases 23,400 Shares of GSK PLC Sponsored ADR $GSK
Bard Financial Services Inc. increased its stake in GSK PLC Sponsored ADR (NYSE:GSK) by 17.4% in the third quarter, acquiring an additional 23,400 shares and bringing its total holdings to 158,145 shares valued at approximately $6.83 million. Other institutional investors also adjusted their positions in GSK. The company reported strong quarterly earnings, beating analyst estimates, and provided positive FY2025 guidance.
Dec 26, 2025 • ts2.tech
SOMEWHAT-BULLISH
GSK plc Stock (NYSE: GSK, LSE: GSK): Latest News, Forecasts, and Key Catalysts as of Dec. 26, 2025
This article provides a comprehensive overview of GSK plc's stock performance and critical developments as of December 26, 2025. It highlights recent U.S. FDA approval for its asthma biologic, significant U.S. drug-pricing agreements, and regulatory momentum for vaccines in Europe, alongside competitive pressures on its Shingrix vaccine. The piece also discusses GSK's raised 2025 financial guidance and analyst forecasts for 2026, emphasizing key catalysts like pipeline execution, pricing policy, and franchise defense that will influence future share performance.
Dec 24, 2025 • ts2.tech
SOMEWHAT-BULLISH
GSK plc Stock: Latest News, Share Price Today, Analyst Forecasts and 2026 Outlook (December 24, 2025)
This article provides a comprehensive overview of GSK plc's performance and outlook as of December 24, 2025. It highlights several key developments including a U.S. drug-pricing agreement, the sale of a manufacturing site to Samsung Biologics, and FDA approvals for new asthma and gonorrhea treatments. The report also details EU recommendations for expanded RSV vaccine use and GSK's ongoing share buyback program, alongside analyst forecasts for 2026 and beyond.
Dec 24, 2025 • University of Cambridge
NEUTRAL
Cambridge and GSK announce new partnership to advance our understanding of the role of cells and tissues in disease, paving the way for new medical breakthroughs
The University of Cambridge and GSK have announced a new partnership aimed at advancing the understanding of cells and tissues in health and disease. GSK is investing nearly £10 million in this collaboration, which will utilize state-of-the-art genomics and machine learning. The partnership brings together expertise from the Teichmann Laboratory at the Cambridge Stem Cell Institute and GSK's scientific capabilities, building on their existing £50 million Translational Immunology Collaboration.